Monte Rosa Therapeutics, Inc. (GLUE)

For the year ended 2025-12-31, Monte Rosa Therapeutics, Inc. reported revenue of $123.67M. Revenue grew 63.5% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $28.73M.

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.